Memorial Sloan-Kettering Cancer Center expert Steven M. Horwitz, MD, discussed and answered participants’ questions about non-Hodgkin’s lymphoma (NHL) during a live Web chat on November 5, 2013. Topics included:
- Features of these diseases
- Advances in diagnosis
- Prognostic tools available to better select treatments for patients most likely to respond
- New treatments, new drug combinations, and ways to make therapy more effective
- On the horizon: clinical trials and vaccines
- Survivorship and quality of life
Dr. Horwitz is a medical oncologist specializing in lymphoma at Memorial Sloan-Kettering Cancer Center. His research is aimed at developing an improved understanding of new therapies for patients with lymphoma, including T cell lymphomas, cutaneous (skin) lymphomas, Hodgkin lymphoma and others. Click here for Dr. Horwitz’s biography.
The majority of lymphomas can be effectively treated and optimal treatment of lymphoma may consist of chemotherapy, radiation, stem cell transplant, targeted therapies, or radio-immunotherapy used alone or in combination. The type of treatment used is determined by the type (histologic diagnosis) and stage of the lymphoma. Understanding standard treatment options and how and when to access new and innovative therapies available through clinical trials is essential in order to achieve the best outcome.
Access the Archived Version of the Web Chat
You can access the archived version of the Web Chat here once it is available. Thank you for your participation.
The Web Chat with the Expert series is not intended to be a substitute for advice from a healthcare professional, diagnosis, or treatment. Speak to your healthcare provider about any questions you may have regarding your health.
Knowledge is power. Are you facing a new diagnosis, recurrence, living with cancer, or supporting a loved one through their cancer journey?